Fig. 6: Effect of hG6PC S298C mRNA-LNP on prevention of hepatic adenomas in L.G6pc−/− mice. | Nature Communications

Fig. 6: Effect of hG6PC S298C mRNA-LNP on prevention of hepatic adenomas in L.G6pc−/− mice.

From: mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease

Fig. 6

a Number of mice with tumors (left), number of tumors per mouse (middle), and tumor burden/area (right). Data were presented as mean ± s.e.m (n = 21, 26, and 34 mice per group for wild-type (WT) treated with PBS, L.G6pc−/− treated with eGFP, and hG6PC S298C mRNA, respectively). b Liver morphology (tumor-circled in yellow) (top panels) and liver histology (bottom panels) of WT and L.G6pc−/− mice treated with either eGFP mRNA or hG6PC S298C mRNAs. c HCA/HCC biomarkers (protein expression). Results are expressed as mean ± SD (n = 15, 27, and 35 mice per group for WT treated with PBS, L.G6pc−/− treated with eGFP, and L.G6pc−/− treated with hG6PC S298C mRNA, respectively). For statistical analysis, raw values were subjected to one-way ANOVA, followed by the Dunnett’s multiple comparisons test, compared to the eGFP mRNA treated group. Statistically significant P values (p ≤ 0.05) are shown in the graphs. Source data are provided as a Source Data File.

Back to article page